LutrePulse Hypogonadotropic Hypogonadism

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Ferring Pharmaceuticals
Information provided by (Responsible Party):
Ferring Pharmaceuticals Identifier:
First received: October 15, 2013
Last updated: May 9, 2016
Last verified: May 2016
To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo

Condition Intervention Phase
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Drug: Gonadorelin acetate 10µg/pulse
Drug: Gonadorelin acetate 15µg/pulse
Drug: Gonadorelin acetate 20µg/pulse
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Ovulation rate [ Time Frame: Treatment Days 19 - 25 ] [ Designated as safety issue: No ]
    calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL

Secondary Outcome Measures:
  • Proportion of subjects with presence of gestational sac and fetal heart movement on transvaginal ultrasound after a second positive serum pregnancy test [ Time Frame: 2 to 4 weeks after a second positive pregnancy test ] [ Designated as safety issue: No ]
  • Proportion of subjects with a confirmed positive serum pregnancy test after luteinizing hormone (LH) surge [ Time Frame: Approximately 14 days after LH surge ] [ Designated as safety issue: No ]
  • Number of follicles with a mean diameter ≥14 mm [ Time Frame: From Day 10 of the treatment period up to approximately 21 full treatment days ] [ Designated as safety issue: No ]
  • Number of dominant follicles with a mean diameter of ≥ 18mm [ Time Frame: From Day 10 of the treatment period up to approximately 21 full treatment days ] [ Designated as safety issue: No ]
  • Maximum progesterone levels [ Time Frame: Treatment Days 19, 21, 23, 25, and 27 ] [ Designated as safety issue: No ]
  • Mean progesterone levels [ Time Frame: Treatment Days 19, 21, 23, 25, and 27 ] [ Designated as safety issue: No ]
  • Change from baseline in follicle-stimulating hormone (FSH) and LH [ Time Frame: Treatment Days 1 and 10 ] [ Designated as safety issue: No ]
  • Mean serum FSH and LH levels [ Time Frame: Treatment Days 1 and 10 ] [ Designated as safety issue: No ]
  • Estradiol serum levels [ Time Frame: At treatment Day 1 and Day 10 ] [ Designated as safety issue: No ]
  • Proportion of subjects with at least 1 post-baseline progesterone level ≥ 10 ng/mL [ Time Frame: Treatment Days 19 - 25 ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: February 2014
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LutrePulse 10µg/pulse
Gonadorelin acetate 10µg/pulse
Drug: Gonadorelin acetate 10µg/pulse
Other Name: LutrePulse
Experimental: LutrePulse 15µg/pulse
Gonadorelin acetate 15µg/pulse
Drug: Gonadorelin acetate 15µg/pulse
Other Name: LutrePulse
Experimental: LutrePulse 20µg/pulse
Gonadorelin acetate 20µg/pulse
Drug: Gonadorelin acetate 20µg/pulse
Other Name: LutrePulse
Placebo Comparator: Placebo
Drug: Placebo


Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women 18-40 years old
  • Body mass index (BMI) between 18 and 38 kg/m2
  • Clinical history or recently diagnosed with primary amenorrhea with hypogonadotropic hypogonadism
  • Hormonal values in a centrally analyzed fasting blood sample: FSH <5 IU/L and mean LH <5 IU/L
  • Desire to become pregnant
  • Discontinued estrogen-progesterone replacement therapy at least 1 month before screening
  • Negative progestin challenge test performed during screening
  • PAP smear within 24 months of the initial visit
  • Normal or stable CT scan or MRI scan of the hypothalamic pituitary region
  • Prolactin and thyroid-stimulating hormone (TSH) within normal clinical laboratory limits
  • Male partner with normal semen analysis, including volume, liquefaction time, sperm count, and motility, according to the local laboratory normal criteria, within the past year
  • Normal transvaginal ultrasound at screening with respect to uterus and adnexa (presence of both ovaries and tubes, without evidence of clinically significant abnormality) and with normal uterine cavity and normal cervix
  • Tube patency on saline tubal perfusion, hysterosalpingography or laparoscopy on file within the past 2 years

Exclusion Criteria:

  • Any medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the drug
  • A history of, or currently diagnosed with clinically important cardiovascular, pulmonary (e.g. serious corticosteroid-dependent asthma), gastrointestinal, hepatic, metabolic, renal, endocrinological (e.g. insulin dependent diabetes mellitus), or neurological (e.g. epilepsy, serious migraine, central nervous system (CNS) lesions (in cases where hypogonadotropic hypogonadism is secondary to a CNS lesion or its treatment) abnormality
  • A history of adrenal or uncontrolled thyroid disorders, or hyperprolactinemia
  • Prior treatment cycle with gonadotropins or GnRH within the last 2 months
  • Known allergy to study drug or its components
  • Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
  • Ovarian enlargement or cyst of unknown etiology
  • Abnormal gynecological bleeding of undetermined origin
  • Previous or current hormone-dependent tumor
  • Known active substance abuse
  • Planning to undergo in vitro fertilization procedure in the course of a study treatment cycle
  • Currently undergoing treatment with gonadotropin hormones (FSH and LH), psychotropic medication, sex hormones, or any other medication known to interfere with normal reproductive function or that can affect GnRH secretion (e.g. neuroleptics, dopamine antagonists, spironolactone, levodopa, phenothiazine, digoxin)
  • Ongoing pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01976728

Contact: Clinical Development Support

  Show 37 Study Locations
Sponsors and Collaborators
Ferring Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals Identifier: NCT01976728     History of Changes
Other Study ID Numbers: 000070 
Study First Received: October 15, 2013
Last Updated: May 9, 2016
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Additional relevant MeSH terms:
Endocrine System Diseases
Gonadal Disorders
Menstruation Disturbances
Pathologic Processes processed this record on May 23, 2016